Human Gene TP53 (ENST00000620739.4) Description and Page Index
  Description: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Induces the transcription of long intergenic non- coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53- inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. (from UniProt P04637)
RefSeq Summary (NM_000546): This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016].
Gencode Transcript: ENST00000620739.4
Gencode Gene: ENSG00000141510.17
Transcript (Including UTRs)
   Position: hg38 chr17:7,668,402-7,687,538 Size: 19,137 Total Exon Count: 11 Strand: -
Coding Region
   Position: hg38 chr17:7,669,609-7,676,251 Size: 6,643 Coding Exon Count: 8 

Page IndexSequence and LinksUniProtKB CommentsMalaCardsCTDRNA-Seq Expression
Microarray ExpressionRNA StructureProtein StructureOther SpeciesGO AnnotationsmRNA Descriptions
PathwaysOther NamesGeneReviewsMethods
Data last updated: 2019-09-04

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr17:7,668,402-7,687,538)mRNA (may differ from genome)Protein (354 aa)
Gene SorterGenome BrowserOther Species FASTAGene interactionsTable SchemaBioGPS
CGAPEnsemblExonPrimerGeneCardsHGNCLynx
MGIneXtProtPubMedReactomeStanford SOURCEUniProtKB
Wikipedia

-  Comments and Description Text from UniProtKB
  ID: P53_HUMAN
DESCRIPTION: RecName: Full=Cellular tumor antigen p53; AltName: Full=Antigen NY-CO-13; AltName: Full=Phosphoprotein p53; AltName: Full=Tumor suppressor p53;
FUNCTION: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Induces the transcription of long intergenic non- coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53- inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
COFACTOR: Binds 1 zinc ion per subunit.
SUBUNIT: Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer- associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with human cytomegalovirus/HHV-5 protein UL123.
INTERACTION: Self; NbExp=3; IntAct=EBI-366083, EBI-366083; P03070:- (xeno); NbExp=6; IntAct=EBI-366083, EBI-617698; O15169:AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; P10415:BCL2; NbExp=3; IntAct=EBI-366083, EBI-77694; Q07817-1:BCL2L1; NbExp=18; IntAct=EBI-366083, EBI-287195; Q9NPI1:BRD7; NbExp=8; IntAct=EBI-366083, EBI-711221; Q9BX70:BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; Q9ESJ1:Cables1 (xeno); NbExp=3; IntAct=EBI-366083, EBI-604411; P17676:CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; Q92793:CREBBP; NbExp=6; IntAct=EBI-366083, EBI-81215; P45481:Crebbp (xeno); NbExp=6; IntAct=EBI-366083, EBI-296306; P55060:CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; Q14999:CUL7; NbExp=3; IntAct=EBI-366083, EBI-308606; Q8IWT3:CUL9; NbExp=2; IntAct=EBI-366083, EBI-311123; Q9UER7:DAXX; NbExp=11; IntAct=EBI-366083, EBI-77321; Q92841:DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; P17844:DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; Q9BV47:DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; Q09472:EP300; NbExp=7; IntAct=EBI-366083, EBI-447295; Q86XK2:FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; Q13547:HDAC1; NbExp=3; IntAct=EBI-366083, EBI-301834; Q86Z02:HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; Q9BUJ2:HNRNPUL1; NbExp=11; IntAct=EBI-366083, EBI-1018153; P38646:HSPA9; NbExp=2; IntAct=EBI-366083, EBI-354932; P42858:HTT; NbExp=4; IntAct=EBI-366083, EBI-466029; Q7Z6Z7:HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; Q16666-2:IFI16; NbExp=3; IntAct=EBI-366083, EBI-6273540; Q92993:KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; P43356:MAGEA2B; NbExp=6; IntAct=EBI-366083, EBI-5650739; Q9UBF1:MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; Q15759:MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; Q8IW41:MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; Q00987:MDM2; NbExp=27; IntAct=EBI-366083, EBI-389668; O15151:MDM4; NbExp=4; IntAct=EBI-366083, EBI-398437; Q8IZD2:MLL5; NbExp=4; IntAct=EBI-366083, EBI-2689959; P23511:NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; Q9Y3T9:NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; P06748:NPM1; NbExp=3; IntAct=EBI-366083, EBI-78579; P06748-1:NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; O60285:NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; P09874:PARP1; NbExp=3; IntAct=EBI-366083, EBI-355676; Q96KB5:PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; O75925:PIAS1; NbExp=3; IntAct=EBI-366083, EBI-629434; Q8N2W9:PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; Q13526:PIN1; NbExp=11; IntAct=EBI-366083, EBI-714158; P29590:PML; NbExp=3; IntAct=EBI-366083, EBI-295890; Q08752:PPID; NbExp=4; IntAct=EBI-366083, EBI-716596; P36873-1:PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; Q8WUF5:PPP1R13L; NbExp=3; IntAct=EBI-366083, EBI-5550163; Q05397:PTK2; NbExp=11; IntAct=EBI-366083, EBI-702142; Q06609:RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; Q8WTS6:SETD7; NbExp=6; IntAct=EBI-366083, EBI-1268586; Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; Q96EB6:SIRT1; NbExp=13; IntAct=EBI-366083, EBI-1802965; Q923E4:Sirt1 (xeno); NbExp=4; IntAct=EBI-366083, EBI-1802585; Q12772:SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; P20226:TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; Q9H3D4:TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; O88898:Tp63 (xeno); NbExp=2; IntAct=EBI-366083, EBI-2338025; Q15672:TWIST1; NbExp=6; IntAct=EBI-366083, EBI-1797287; Q05086:UBE3A; NbExp=2; IntAct=EBI-366083, EBI-954357; Q96PU4:UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; Q93009:USP7; NbExp=10; IntAct=EBI-366083, EBI-302474; P11473:VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; Q14191:WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; P12956:XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; Q9PST7:znf585b (xeno); NbExp=3; IntAct=EBI-366083, EBI-1782562;
SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2.
SUBCELLULAR LOCATION: Isoform 1: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.
SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.
SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.
SUBCELLULAR LOCATION: Isoform 7: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
SUBCELLULAR LOCATION: Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.
SUBCELLULAR LOCATION: Isoform 9: Cytoplasm.
TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not induced in tumor cells in response to stress.
DOMAIN: The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.
PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
PTM: Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53- mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was intially thought to be mediated by STK11/LKB1 but it was later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53, particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- damage.
PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
PTM: May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys- 370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
PTM: Sumoylated with SUMO1.
DISEASE: Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
DISEASE: Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
DISEASE: Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
DISEASE: Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
DISEASE: Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
DISEASE: Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
DISEASE: Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li- Fraumeni syndrome.
SIMILARITY: Belongs to the p53 family.
WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and germline TP53 mutations in human cancers; URL="http://www-p53.iarc.fr/";
WEB RESOURCE: Name=The TP53 mutant web site; Note=TP53 mutations and cancer; URL="http://p53.fr/";
WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/P53ID88.html";
WEB RESOURCE: Name=GeneReviews; URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/TP53";
WEB RESOURCE: Name=NIEHS-SNPs; URL="http://egp.gs.washington.edu/data/tp53/";
WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and polymorphism database; URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53";
WEB RESOURCE: Name=Wikipedia; Note=P53 entry; URL="http://en.wikipedia.org/wiki/P53";

-  MalaCards Disease Associations
  MalaCards Gene Search: TP53
Diseases sorted by gene-association score: li-fraumeni syndrome* (1762), osteosarcoma, somatic* (1275), choroid plexus papilloma* (1255), adrenal cortical carcinoma* (957), pancreatic cancer* (761), basal cell carcinoma 7* (594), nasopharyngeal carcinoma* (515), hepatocellular carcinoma* (483), choroid plexus cancer* (422), glioma susceptibility 1* (332), breast cancer* (315), small cell cancer of the lung, somatic* (264), megakaryocytic leukemia* (231), chronic lymphocytic leukemia* (216), brca1 hereditary breast and ovarian cancer syndrome* (163), colorectal cancer* (159), brca2 hereditary breast and ovarian cancer syndrome* (141), adenocarcinoma (48), malignant glioma (37), squamous cell carcinoma (35), grade iii astrocytoma (35), papilloma (32), bladder urothelial carcinoma (31), penile cancer (30), cervical cancer, somatic (26), transitional cell carcinoma (25), actinic keratosis (25), serous cystadenocarcinoma (25), bile duct carcinoma (24), barrett's adenocarcinoma (24), basal cell carcinoma (24), brain glioma (24), uterine corpus cancer (23), cervix carcinoma (23), lung cancer (23), skin squamous cell carcinoma (23), intestinal disease (23), bladder transitional cell papilloma (23), conjunctival squamous cell carcinoma (22), xanthogranulomatous cholecystitis (22), papilledema (22), thyroid lymphoma (21), multifocal osteogenic sarcoma (21), glioblastoma multiforme (21), breast ductal carcinoma (21), cell type cancer (20), oral cancer (19), gastroesophageal reflux (19), vulvar intraepithelial neoplasia (18), actinic cheilitis (18), esophageal cancer (18), b cell prolymphocytic leukemia (18), hepadnavirus infection (18), ovary epithelial cancer (17), malignant ovarian surface epithelial-stromal neoplasm (17), atrophy of prostate (17), verrucous carcinoma (17), basaloid squamous cell carcinoma (17), ovarian serous carcinoma (17), endometrial cancer (17), mixed cell type cancer (16), fallopian tube carcinoma (16), cheilitis (16), urinary bladder cancer (16), cll/sll (16), astrocytoma (16), anal squamous cell carcinoma (15), necrotizing sialometaplasia (15), mature teratoma (15), ulcerative stomatitis (15), invasive bladder transitional cell carcinoma (15), hereditary breast ovarian cancer* (15), kidney cancer (14), vulvar sebaceous carcinoma (14), blastoma (14), endometrial adenocarcinoma (14), cystadenocarcinoma (14), bladder cancer, somatic (14), pleomorphic xanthoastrocytoma (14), richter's syndrome (14), larynx cancer (14), in situ carcinoma (14), gallbladder cancer (14), lung occult squamous cell carcinoma (14), clivus meningioma (14), mixed astrocytoma-ependymoma (14), giant cell glioblastoma* (14), parietal lobe neoplasm (14), spinal cord primitive neuroectodermal neoplasm (14), mixed oligodendroglioma-astrocytoma (14), penis carcinoma in situ (14), submandibular gland cancer (14), parameningeal embryonal rhabdomyosarcoma (14), central nervous system lymphoma (13), oral squamous cell carcinoma (13), clear cell cystadenofibroma (13), plantar wart (13), keratocystic odontogenic tumor (13), pleuropulmonary blastoma (13), pulmonary blastoma (13), balkan nephropathy (13), lung benign neoplasm (13), essential thrombocythemia* (13), esophageal basaloid squamous cell carcinoma (13), vulva cancer (13), pancreatic ductal adenocarcinoma (13), scrotal carcinoma (13), adult hepatocellular carcinoma* (12), gliomatosis cerebri (12), familial adenomatous polyposis (12), inverted papilloma (12), gastric lymphoma (12), lip cancer (12), ataxia-telangiectasia (12), stomach cancer (12), breast carcinoma in situ (12), ovarian cancer, somatic (12), tongue squamous cell carcinoma (12), gastrointestinal system benign neoplasm (12), uterine carcinosarcoma (11), mixed glioma (11), ductal carcinoma in situ (11), gastrointestinal system cancer (11), colorectal adenocarcinoma (11), uterine corpus serous adenocarcinoma (11), acinar cell carcinoma (11), maxillary sinus squamous cell carcinoma (11), microglandular adenosis (11), vulva squamous cell carcinoma (11), barrett esophagus/esophageal adenocarcinoma (11), female reproductive endometrioid cancer (11), cerebellum cancer (11), pleomorphic carcinoma (11), gliosarcoma* (11), breast adenocarcinoma (11), cerebellar astrocytoma (11), cell type benign neoplasm (11), chordoid glioma (11), nevus of ota (10), glioma (10), bone giant cell sarcoma (10), brain cancer (10), gliofibroma (10), squamous cell carcinoma, head and neck (10), cystic teratoma (10), ring chromosome 7 (10), fibrillary astrocytoma (10), cholecystitis (10), glioblastoma (10), endocervical adenocarcinoma (10), colorectal adenoma (10), glomangiosarcoma (10), cellular neurofibroma (10), endometrium carcinoma in situ (10), myasthenic syndrome, congenital, 17 (10), soft tissue sarcoma (10), myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects (9), keratoacanthoma (9), frontal convexity meningioma (9), cerebellar angioblastoma (9), kaposi sarcoma (9), larynx verrucous carcinoma (9), epidermal appendage tumor (9), splenic diffuse red pulp small b-cell lymphoma (9), mucoepidermoid esophageal carcinoma (9), esophagus adenocarcinoma (9), lichen sclerosus (9), sarcoma (9), rhabdomyosarcoma (9), esophagitis (9), granulosa cell tumor of the ovary (9), intrahepatic cholangiocarcinoma (9), spitz nevus (9), integumentary system cancer (9), bladder papillary transitional cell neoplasm (9), urinary tract papillary transitional cell benign neoplasm (9), skin melanoma (9), breast malignant phyllodes tumor (9), primary peritoneal carcinoma (9), small cell neuroendocrine carcinoma (9), ovarian clear cell carcinoma (9), hidradenocarcinoma (9), spiradenoma (9), cervical adenocarcinoma (9), sporadic breast cancer (9), b-cell lymphomas (9), non-invasive bladder papillary urothelial neoplasm (9), pre-malignant neoplasm (9), pleomorphic rhabdomyosarcoma (9), embryonal sarcoma (9), pleomorphic adenoma carcinoma (9), female breast cancer (9), pancreatic ductal carcinoma (8), ganglioglioma (8), tongue cancer (8), oral leukoplakia (8), brooke-spiegler syndrome (8), bile duct adenocarcinoma (8), pigmented villonodular synovitis (8), meninges sarcoma (8), xeroderma pigmentosum, variant type (8), calcifying epithelial odontogenic tumor (8), malignant spiradenoma (8), biliary tract neoplasm (8), lung cancer susceptibility 3 (8), bartholin's duct cyst (8), intracranial chondrosarcoma (8), marek disease (8), penis squamous cell carcinoma (8), ovary adenocarcinoma (8), brain ependymoma (8), tetraploidy (8), short-rib thoracic dysplasia 4 with or without polydactyly (8), female reproductive organ cancer (8), retinal cancer (8), sensory system cancer (8), mantle cell lymphoma (8), vestibular gland benign neoplasm (8), endometrial clear cell adenocarcinoma (8), bartholin's gland adenoma (8), adult t-cell leukemia (8), brain stem astrocytic neoplasm (8), peutz-jeghers syndrome (8), medulloblastoma (7), glomus tumor (7), uterine body mixed cancer (7), histiocytoma (7), nijmegen breakage syndrome (7), xeroderma pigmentosum, group a (7), oligodendroglioma (7), dedifferentiated liposarcoma (7), nervous system cancer (7), liposarcoma (7), retinoblastoma (7), mutyh-associated polyposis (7), adenosquamous carcinoma (7), hyperplastic polyposis syndrome (7), supratentorial cancer (7), infratentorial cancer (7), pseudomyxoma peritonei (7), protoplasmic astrocytoma (7), small cell carcinoma (7), reproductive organ cancer (7), bladder carcinoma in situ (7), lung squamous cell carcinoma (7), brain stem cancer (7), estrogen-receptor positive breast cancer (7), rift valley fever (7), myxoid liposarcoma (7), pharynx cancer (7), clear cell adenocarcinoma (7), mucinous adenocarcinoma (7), papillary glioneuronal tumor (7), sweat gland cancer (7), sapho syndrome (7), merkel cell carcinoma (7), connective tissue cancer (7), eccrine sweat gland neoplasm (7), cervical squamous cell carcinoma (7), mutagen sensitivity (7), cerebrum cancer (7), gastrointestinal carcinoma (7), autonomic nervous system neoplasm (7), spinal cord astrocytoma (7), gastric cardia adenocarcinoma (6), diffuse large b-cell lymphoma (6), oropharynx cancer (6), lung papillary adenocarcinoma (6), papillary serous adenocarcinoma (6), adamantinoma of long bones (6), malignant giant cell tumor (6), lymph node cancer (6), brain stem glioma (6), rectal neoplasm (6), cerebral neuroblastoma (6), achalasia (6), lynch syndrome (6), brain glioblastoma multiforme (6), cervix uteri carcinoma in situ (6), thymus cancer (6), angiosarcoma (6), malignant ependymoma (6), uterine corpus endometrial carcinoma (6), peripheral nervous system neoplasm (6), bizarre leiomyoma (6), keratosis (6), lichen planus (6), cerebral convexity meningioma (6), pleomorphic adenoma (6), keratinizing squamous cell carcinoma (6), prostate adenocarcinoma (6), intestinal benign neoplasm (6), leiomyosarcoma (6), malignant fibroxanthoma (6), teratoma (6), cerebral ventricle cancer (6), dermatofibrosarcoma protuberans (6), atrophic gastritis (6), leukemia, acute lymphoblastic 3* (6), thyroid cancer (6), melanoma (6), breast disease (6), ependymoblastoma (6), central nervous system primitive neuroectodermal neoplasm (6), biliary papillomatosis (6), acute lymphocytic leukemia (6), esophageal disease (6), breast benign neoplasm (6), thoracic benign neoplasm (6), spinal cancer (6), prolactin producing pituitary tumor (6), testicular germ cell tumor (6), ureteral obstruction (6), adenoma (6), cervical carcinosarcoma (5), hypoxia (5), lip disease (5), prostate cancer (5), sarcomatoid squamous cell skin carcinoma (5), ocular cancer (5), fallopian tube adenocarcinoma (5), bartholin's gland benign neoplasm (5), squamous cell papilloma (5), inflammatory myofibroblastic tumor (5), malignant peripheral nerve sheath tumor (5), nervous system benign neoplasm (5), male reproductive organ cancer (5), endometrial stromal sarcoma (5), clear cell renal cell carcinoma (5), organ system benign neoplasm (5), central nervous system organ benign neoplasm (5), muscle cancer (5), myxosarcoma (5), endocervical carcinoma (5), olfactory groove meningioma (5), atypical follicular adenoma (5), childhood leukemia (5), nasal cavity adenocarcinoma (5), pancreas adenocarcinoma (5), synchronous bilateral breast carcinoma (5), cataract 24, anterior polar (5), sclerosing liposarcoma (5), glycogen-rich clear cell breast carcinoma (5), hydrocephalus (5), anogenital venereal wart (5), juvenile pilocytic astrocytoma (5), familial colorectal cancer (5), tonsil cancer (5), non-proliferative fibrocystic change of the breast (5), epidural neoplasm (5), gastric cancer, somatic (5), multiple cranial nerve palsy (4), anterior cranial fossa meningioma (4), ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 (4), meningeal melanomatosis (4), liver angiosarcoma (4), bone squamous cell carcinoma (4), duodenum cancer (4), signet ring cell adenocarcinoma (4), clear cell ependymoma (4), cervix small cell carcinoma (4), breast metaplastic carcinoma (4), mature b-cell neoplasm (4), cerebral primitive neuroectodermal tumor (4), agraphia (4), lichen disease (4), periosteal osteogenic sarcoma (4), adult medulloblastoma (4), small cell sarcoma (4), cellular schwannoma (4), chronic salpingitis (4), bladder squamous cell carcinoma (4), cribriform carcinoma (4), conjunctival degeneration (4), localized osteosarcoma (4), chromophobe adenoma (4), medullomyoblastoma (4), malignant mesenchymoma (4), cerebellar liponeurocytoma (3), optic nerve neoplasm (3), split-hand/foot malformation 4 (3), huntington disease (3), pinguecula (3), optic nerve glioma (3), vaccinia (3), malignant melanoma, somatic (3), differentiated thyroid carcinoma (3), mucoepidermoid carcinoma (3), cystitis (3), chordoma (3), gastrointestinal stromal tumor (2), acquired immunodeficiency syndrome (2), multiple myeloma (2), aplastic anemia (2), uveal melanoma (2), ewing sarcoma (2), endocrine gland cancer (2), neuroblastoma (2), autosomal genetic disease (2), germ cell and embryonal cancer (1), meningioma, familial (1), leukemia, acute myeloid (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 38.06 RPKM in Cells - EBV-transformed lymphocytes
Total median expression: 470.82 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -111.30307-0.363 Picture PostScript Text
3' UTR -393.101207-0.326 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR008967 - p53-like_TF_DNA-bd
IPR012346 - p53/RUNT-type_TF_DNA-bd
IPR011615 - p53_DNA-bd
IPR010991 - p53_tetrameristn
IPR013872 - p53_transactivation_domain
IPR002117 - p53_tumour_suppressor

Pfam Domains:
PF00870 - P53 DNA-binding domain
PF08563 - P53 transactivation motif
PF07710 - P53 tetramerisation motif

Protein Data Bank (PDB) 3-D Structure
MuPIT help

1A1U
- NMR MuPIT

1AIE
- X-ray MuPIT

1C26
- X-ray MuPIT
To conserve bandwidth, only the images from the first 3 structures are shown.
1DT7 - NMR 1GZH - X-ray MuPIT 1H26 - X-ray
1HS5 - NMR MuPIT 1JSP - NMR MuPIT 1KZY - X-ray MuPIT
1MA3 - X-ray 1OLG - NMR MuPIT 1OLH - NMR MuPIT
1PES - NMR MuPIT 1PET - NMR MuPIT 1SAE - NMR
1SAF - NMR 1SAK - NMR 1SAL - NMR
1TSR - X-ray MuPIT 1TUP - X-ray MuPIT 1UOL - X-ray MuPIT
1XQH - X-ray MuPIT 1YC5 - X-ray 1YCQ - X-ray
1YCR - X-ray MuPIT 1YCS - X-ray 2AC0 - X-ray MuPIT
2ADY - X-ray MuPIT 2AHI - X-ray MuPIT 2ATA - X-ray MuPIT
2B3G - X-ray MuPIT 2BIM - X-ray MuPIT 2BIN - X-ray MuPIT
2BIO - X-ray MuPIT 2BIP - X-ray MuPIT 2BIQ - X-ray MuPIT
2F1X - X-ray MuPIT 2FEJ - NMR MuPIT 2FOJ - X-ray MuPIT
2FOO - X-ray MuPIT 2GS0 - NMR 2H1L - X-ray MuPIT
2H2D - X-ray 2H2F - X-ray 2H4F - X-ray
2H4H - X-ray 2H4J - X-ray 2H59 - X-ray
2J0Z - NMR 2J10 - NMR 2J11 - NMR
2J1W - X-ray MuPIT 2J1X - X-ray MuPIT 2J1Y - X-ray MuPIT
2J1Z - X-ray MuPIT 2J20 - X-ray MuPIT 2J21 - X-ray MuPIT
2K8F - NMR MuPIT 2L14 - NMR MuPIT 2OCJ - X-ray MuPIT
2PCX - X-ray MuPIT 2QVQ - X-ray 2QXA - X-ray
2QXB - X-ray 2QXC - X-ray 2VUK - X-ray MuPIT
2WGX - X-ray MuPIT 2X0U - X-ray MuPIT 2X0V - X-ray MuPIT
2X0W - X-ray MuPIT 2XWR - X-ray MuPIT 2YBG - X-ray MuPIT
2Z5S - X-ray 2Z5T - X-ray 3D05 - X-ray MuPIT
3D06 - X-ray MuPIT 3D07 - X-ray MuPIT 3D08 - X-ray MuPIT
3D09 - X-ray MuPIT 3D0A - X-ray MuPIT 3DAB - X-ray MuPIT
3DAC - X-ray 3IGK - X-ray MuPIT 3IGL - X-ray MuPIT
3KMD - X-ray 3KZ8 - X-ray MuPIT 3LW1 - X-ray MuPIT
3OQ5 - X-ray MuPIT 3PDH - X-ray 3Q01 - X-ray MuPIT
3Q05 - X-ray MuPIT 3Q06 - X-ray MuPIT 3SAK - NMR
3TG5 - X-ray MuPIT 3TS8 - X-ray MuPIT 4AGL - X-ray MuPIT
4AGM - X-ray MuPIT 4AGN - X-ray MuPIT 4AGO - X-ray MuPIT
4AGP - X-ray MuPIT 4AGQ - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P04637
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
Genome BrowserGenome BrowserNo orthologNo orthologNo orthologNo ortholog
Gene Details     
Gene Sorter     
MGIRGD    
Protein SequenceProtein Sequence    
AlignmentAlignment    

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000981 RNA polymerase II transcription factor activity, sequence-specific DNA binding
GO:0000990 transcription factor activity, core RNA polymerase binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001074 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding involved in preinitiation complex assembly
GO:0001085 RNA polymerase II transcription factor binding
GO:0001094 TFIID-class transcription factor binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0002020 protease binding
GO:0002039 p53 binding
GO:0003677 DNA binding
GO:0003682 chromatin binding
GO:0003684 damaged DNA binding
GO:0003700 transcription factor activity, sequence-specific DNA binding
GO:0003730 mRNA 3'-UTR binding
GO:0005507 copper ion binding
GO:0005515 protein binding
GO:0005524 ATP binding
GO:0008134 transcription factor binding
GO:0008270 zinc ion binding
GO:0019899 enzyme binding
GO:0019901 protein kinase binding
GO:0019903 protein phosphatase binding
GO:0030971 receptor tyrosine kinase binding
GO:0031625 ubiquitin protein ligase binding
GO:0035035 histone acetyltransferase binding
GO:0042802 identical protein binding
GO:0042826 histone deacetylase binding
GO:0043621 protein self-association
GO:0044212 transcription regulatory region DNA binding
GO:0046872 metal ion binding
GO:0046982 protein heterodimerization activity
GO:0047485 protein N-terminus binding
GO:0051087 chaperone binding
GO:0051721 protein phosphatase 2A binding
GO:0097718 disordered domain specific binding
GO:1990841 promoter-specific chromatin binding

Biological Process:
GO:0000122 negative regulation of transcription from RNA polymerase II promoter
GO:0000733 DNA strand renaturation
GO:0006284 base-excision repair
GO:0006289 nucleotide-excision repair
GO:0006351 transcription, DNA-templated
GO:0006355 regulation of transcription, DNA-templated
GO:0006366 transcription from RNA polymerase II promoter
GO:0006914 autophagy
GO:0006915 apoptotic process
GO:0006974 cellular response to DNA damage stimulus
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator
GO:0006983 ER overload response
GO:0007049 cell cycle
GO:0007050 cell cycle arrest
GO:0007265 Ras protein signal transduction
GO:0007275 multicellular organism development
GO:0007569 cell aging
GO:0008104 protein localization
GO:0008283 cell proliferation
GO:0008285 negative regulation of cell proliferation
GO:0008340 determination of adult lifespan
GO:0009299 mRNA transcription
GO:0010165 response to X-ray
GO:0010332 response to gamma radiation
GO:0010628 positive regulation of gene expression
GO:0012501 programmed cell death
GO:0016032 viral process
GO:0016579 protein deubiquitination
GO:0019221 cytokine-mediated signaling pathway
GO:0030154 cell differentiation
GO:0030308 negative regulation of cell growth
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0031065 positive regulation of histone deacetylation
GO:0031497 chromatin assembly
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0032461 positive regulation of protein oligomerization
GO:0034613 cellular protein localization
GO:0034644 cellular response to UV
GO:0035690 cellular response to drug
GO:0042149 cellular response to glucose starvation
GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:0042981 regulation of apoptotic process
GO:0043065 positive regulation of apoptotic process
GO:0043066 negative regulation of apoptotic process
GO:0043153 entrainment of circadian clock by photoperiod
GO:0043525 positive regulation of neuron apoptotic process
GO:0045892 negative regulation of transcription, DNA-templated
GO:0045893 positive regulation of transcription, DNA-templated
GO:0045899 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly
GO:0045944 positive regulation of transcription from RNA polymerase II promoter
GO:0046677 response to antibiotic
GO:0046827 positive regulation of protein export from nucleus
GO:0046902 regulation of mitochondrial membrane permeability
GO:0048147 negative regulation of fibroblast proliferation
GO:0048511 rhythmic process
GO:0048512 circadian behavior
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0051097 negative regulation of helicase activity
GO:0051123 RNA polymerase II transcriptional preinitiation complex assembly
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0051974 negative regulation of telomerase activity
GO:0065003 macromolecular complex assembly
GO:0070245 positive regulation of thymocyte apoptotic process
GO:0071158 positive regulation of cell cycle arrest
GO:0071456 cellular response to hypoxia
GO:0071479 cellular response to ionizing radiation
GO:0071480 cellular response to gamma radiation
GO:0072331 signal transduction by p53 class mediator
GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator
GO:0072717 cellular response to actinomycin D
GO:0090200 positive regulation of release of cytochrome c from mitochondria
GO:0090399 replicative senescence
GO:0090403 oxidative stress-induced premature senescence
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097252 oligodendrocyte apoptotic process
GO:1900119 positive regulation of execution phase of apoptosis
GO:1900740 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1902749 regulation of cell cycle G2/M phase transition
GO:1902895 positive regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1990440 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway

Cellular Component:
GO:0000790 nuclear chromatin
GO:0005622 intracellular
GO:0005634 nucleus
GO:0005654 nucleoplasm
GO:0005657 replication fork
GO:0005730 nucleolus
GO:0005737 cytoplasm
GO:0005739 mitochondrion
GO:0005759 mitochondrial matrix
GO:0005783 endoplasmic reticulum
GO:0005829 cytosol
GO:0016363 nuclear matrix
GO:0016605 PML body
GO:0032991 macromolecular complex
GO:0005669 transcription factor TFIID complex
GO:0016604 nuclear body


-  Descriptions from all associated GenBank mRNAs
  EF101869 - Homo sapiens cell-line HDLM2 nonfunctional tumor suppressor p53 (TP53) mRNA, complete cds.
AM076971 - Homo sapiens partial mRNA for tumor protein p53 mutant form (TP53 gene), classical Hodgkin Lymphoma cell line HDLM-2.
EF101868 - Homo sapiens cell-line L1236 nonfunctional tumor suppressor p53 (TP53) mRNA, complete cds.
AM076972 - Homo sapiens partial mRNA for tumor protein p53 mutant form (TP53 gene), classical Hodgkin Lymphoma cell line L1236.
DQ186650 - Homo sapiens del133 p53 isoform (TP53) mRNA, complete cds.
DQ186651 - Homo sapiens del133 p53 beta isoform (TP53) mRNA, complete cds.
DQ186652 - Homo sapiens del133 p53 gamma isoform (TP53) mRNA, complete cds.
HW061196 - JP 2012529430-A/71: METHODS FOR TREATING CHRONIC KIDNEY DISEASE.
HW061197 - JP 2012529430-A/72: METHODS FOR TREATING CHRONIC KIDNEY DISEASE.
HW061198 - JP 2012529430-A/73: METHODS FOR TREATING CHRONIC KIDNEY DISEASE.
JA482151 - Sequence 134 from Patent WO2011072091.
JA482152 - Sequence 135 from Patent WO2011072091.
JA482153 - Sequence 136 from Patent WO2011072091.
JB252004 - Sequence 71 from Patent EP2440214.
JB252005 - Sequence 72 from Patent EP2440214.
JB252006 - Sequence 73 from Patent EP2440214.
JE980443 - Sequence 134 from Patent EP2862929.
JE980444 - Sequence 135 from Patent EP2862929.
JE980445 - Sequence 136 from Patent EP2862929.
LP764903 - Sequence 71 from Patent EP3276004.
LP764904 - Sequence 72 from Patent EP3276004.
LP764905 - Sequence 73 from Patent EP3276004.
LQ948588 - Sequence 5 from Patent WO2014043292.
LQ948589 - Sequence 6 from Patent WO2014043292.
LQ948590 - Sequence 7 from Patent WO2014043292.
JN900492 - Homo sapiens tumor suppressor TP53 (TP53) mRNA, complete cds, alternatively spliced.
HW061192 - JP 2012529430-A/67: METHODS FOR TREATING CHRONIC KIDNEY DISEASE.
HW061193 - JP 2012529430-A/68: METHODS FOR TREATING CHRONIC KIDNEY DISEASE.
HW061194 - JP 2012529430-A/69: METHODS FOR TREATING CHRONIC KIDNEY DISEASE.
HW061195 - JP 2012529430-A/70: METHODS FOR TREATING CHRONIC KIDNEY DISEASE.
JA482147 - Sequence 130 from Patent WO2011072091.
JA482148 - Sequence 131 from Patent WO2011072091.
JA482149 - Sequence 132 from Patent WO2011072091.
JA482150 - Sequence 133 from Patent WO2011072091.
JB252000 - Sequence 67 from Patent EP2440214.
JB252001 - Sequence 68 from Patent EP2440214.
JB252002 - Sequence 69 from Patent EP2440214.
JB252003 - Sequence 70 from Patent EP2440214.
JE980439 - Sequence 130 from Patent EP2862929.
JE980440 - Sequence 131 from Patent EP2862929.
JE980441 - Sequence 132 from Patent EP2862929.
JE980442 - Sequence 133 from Patent EP2862929.
LP764899 - Sequence 67 from Patent EP3276004.
LP764900 - Sequence 68 from Patent EP3276004.
LP764901 - Sequence 69 from Patent EP3276004.
LP764902 - Sequence 70 from Patent EP3276004.
LQ948584 - Sequence 1 from Patent WO2014043292.
LQ948585 - Sequence 2 from Patent WO2014043292.
LQ948586 - Sequence 3 from Patent WO2014043292.
LQ948587 - Sequence 4 from Patent WO2014043292.
LY486121 - KR 1020170007492-A/1: METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS.
LZ228280 - JP 2017521374-A/1: METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS.
DM163612 - Method for promotion of p53 expression.
HV708907 - JP 2012506450-A/5: Methods for treating eye disorders.
DQ186648 - Homo sapiens p53 beta isoform (TP53) mRNA, complete cds.
DQ186649 - Homo sapiens p53 gamma isoform (TP53) mRNA, complete cds.
DQ286964 - Homo sapiens p53 protein (TP53) mRNA, complete cds, alternatively spliced.
DQ191317 - Homo sapiens p53 protein (TP53) mRNA, complete cds, alternatively spliced.
AF052180 - Homo sapiens clone 24564 mRNA sequence.
AK223026 - Homo sapiens mRNA for tumor protein p53 variant, clone: JTH07296.
X01405 - Human mRNA fragment for phosphoprotein p53.
AB082923 - Homo sapiens mRNA for P53, complete cds.
BC003596 - Homo sapiens tumor protein p53, mRNA (cDNA clone MGC:646 IMAGE:3544714), complete cds.
AF307851 - Homo sapiens p53 protein mRNA, complete cds.
JN214348 - Homo sapiens cell-line HCT116p53-/- nonfunctional delta40-P53 transcript variant (TP53) mRNA, complete sequence.
FJ207420 - Homo sapiens mutant p53 mRNA, complete cds.
DL476262 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941382 - JP 2012152216-A/207: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798288 - JP 2014236738-A/207: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
JD123340 - Sequence 104364 from Patent EP1572962.
JD299783 - Sequence 280807 from Patent EP1572962.
JD378958 - Sequence 359982 from Patent EP1572962.
JD533970 - Sequence 514994 from Patent EP1572962.
JD081653 - Sequence 62677 from Patent EP1572962.
JD460944 - Sequence 441968 from Patent EP1572962.
JD477968 - Sequence 458992 from Patent EP1572962.
JD321581 - Sequence 302605 from Patent EP1572962.
JD064504 - Sequence 45528 from Patent EP1572962.
JD295458 - Sequence 276482 from Patent EP1572962.
JD071890 - Sequence 52914 from Patent EP1572962.
JD398255 - Sequence 379279 from Patent EP1572962.
JD070332 - Sequence 51356 from Patent EP1572962.
JD286216 - Sequence 267240 from Patent EP1572962.
JD480909 - Sequence 461933 from Patent EP1572962.
JD543982 - Sequence 525006 from Patent EP1572962.
JD542311 - Sequence 523335 from Patent EP1572962.
JD542310 - Sequence 523334 from Patent EP1572962.
JD542309 - Sequence 523333 from Patent EP1572962.
JD266224 - Sequence 247248 from Patent EP1572962.
JD564555 - Sequence 545579 from Patent EP1572962.
JD566766 - Sequence 547790 from Patent EP1572962.
JD266223 - Sequence 247247 from Patent EP1572962.
JD297255 - Sequence 278279 from Patent EP1572962.
JD393077 - Sequence 374101 from Patent EP1572962.
JD486665 - Sequence 467689 from Patent EP1572962.
AK297927 - Homo sapiens cDNA FLJ54299 complete cds, highly similar to Cellular tumor antigen p53.
AK297462 - Homo sapiens cDNA FLJ54297 complete cds, highly similar to Cellular tumor antigen p53.
JD168340 - Sequence 149364 from Patent EP1572962.
JD527824 - Sequence 508848 from Patent EP1572962.
K03199 - Human p53 cellular tumor antigen mRNA, complete cds.
AK225838 - Homo sapiens mRNA for Cellular tumor antigen p53 variant, clone: FCC127A11.
JD298986 - Sequence 280010 from Patent EP1572962.
JD168621 - Sequence 149645 from Patent EP1572962.
LP866509 - Sequence 63 from Patent WO2017162888.
JQ694049 - Homo sapiens isolate iPCH358_Col1 tumor suppressor p53 (TP53) mRNA, complete cds.
JQ694050 - Homo sapiens isolate iPCH358_Col3 tumor suppressor p53 (TP53) mRNA, complete cds.
JQ694051 - Homo sapiens isolate iPCH358_Col11 tumor suppressor p53 (TP53) mRNA, complete cds.
JD317542 - Sequence 298566 from Patent EP1572962.
JD059195 - Sequence 40219 from Patent EP1572962.
DQ648886 - Homo sapiens p53+ins9a (TP53) mRNA, 3' UTR, alternatively spliced.
DQ648887 - Homo sapiens p53-Ex10 isoform (TP53) mRNA, partial cds, alternatively spliced.
JQ026208 - Homo sapiens clone c.398-399ins4 mutated tumor suppressor protein P53 mRNA sequence.
JD477257 - Sequence 458281 from Patent EP1572962.
JQ026207 - Homo sapiens clone c.159del1 mutated tumor suppressor protein P53 mRNA sequence.
AM076970 - Homo sapiens partial mRNA for tumor protein p53 mutant form (TP53 gene), classical Hodgkin Lymphoma cell line L428.
DQ263704 - Homo sapiens tumor protein p53 (TP53) mRNA, complete cds.
EF101867 - Homo sapiens cell-line L428 nonfunctional tumor suppressor p53 (TP53) mRNA, complete cds.
JN601513 - Homo sapiens isolate MV4-11 mutant p53 protein mRNA, partial cds.
JN601514 - Homo sapiens isolate Kasumi-1 mutant p53 protein mRNA, partial cds.
JN601515 - Homo sapiens isolate CMS mutant p53 protein mRNA, partial cds.
JN601516 - Homo sapiens isolate THP-1 truncated p53 protein mRNA, partial cds.
JQ026210 - Homo sapiens clone c.792_796del5 mutated tumor suppressor protein P53 mRNA sequence.
MG595979 - Homo sapiens isolate TWH-1414-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595980 - Homo sapiens isolate TWH-0571-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595981 - Homo sapiens isolate TWH-0357-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595982 - Homo sapiens isolate TWH-1016-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595983 - Homo sapiens isolate HKSH-0023-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595984 - Homo sapiens isolate PMH-0020-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595985 - Homo sapiens isolate TWH-0863-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595986 - Homo sapiens isolate TWH-1542-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595987 - Homo sapiens isolate TWH-0104-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595988 - Homo sapiens isolate HKSH-0182-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595989 - Homo sapiens isolate TWH-0855-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595990 - Homo sapiens isolate KWH-0019-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595991 - Homo sapiens isolate TWH-1681-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595992 - Homo sapiens isolate TWH-0602-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
MG595993 - Homo sapiens isolate TWH-0395-0-1 truncated tumor protein p53 (TP53) mRNA, complete cds.
MG595994 - Homo sapiens isolate TWH-1698-0-1 mutant tumor protein p53 (TP53) mRNA, complete cds.
M14695 - Human p53 cellular tumor antigen mRNA, complete cds.
M14694 - Human p53 cellular tumor antigen mRNA, complete cds.
X02469 - Human mRNA for p53 cellular tumor antigen.
AK312568 - Homo sapiens cDNA, FLJ92943, Homo sapiens tumor protein p53 (Li-Fraumeni syndrome) (TP53), mRNA.
KJ897694 - Synthetic construct Homo sapiens clone ccsbBroadEn_07088 TP53 gene, encodes complete protein.
KR709864 - Synthetic construct Homo sapiens clone CCSBHm_00006902 TP53 (TP53) mRNA, encodes complete protein.
KR709865 - Synthetic construct Homo sapiens clone CCSBHm_00006929 TP53 (TP53) mRNA, encodes complete protein.
KR709866 - Synthetic construct Homo sapiens clone CCSBHm_00006983 TP53 (TP53) mRNA, encodes complete protein.
KR709867 - Synthetic construct Homo sapiens clone CCSBHm_00007040 TP53 (TP53) mRNA, encodes complete protein.
BT019622 - Homo sapiens tumor protein p53 (Li-Fraumeni syndrome) mRNA, complete cds.
DQ892492 - Synthetic construct clone IMAGE:100005122; FLH186809.01X; RZPDo839A0972D tumor protein p53 (Li-Fraumeni syndrome) (TP53) gene, encodes complete protein.
DQ895704 - Synthetic construct Homo sapiens clone IMAGE:100010164; FLH186805.01L; RZPDo839A0962D tumor protein p53 (Li-Fraumeni syndrome) (TP53) gene, encodes complete protein.
X60011 - Human mRNA for mutated p53 transformation suppressor gene.
X60012 - Human mRNA for mutated p53 transformation suppressor gene.
X60013 - Human mRNA for mutated p53 transformation suppressor gene.
X60014 - Human mRNA for mutated p53 transformation suppressor gene.
X60015 - Human mRNA for mutated p53 transformation suppressor gene.
X60016 - Human mRNA for mutated p53 transformation suppressor gene.
X60017 - Human mRNA for mutated p53 transformation suppressor gene.
X60018 - Human mRNA for mutated p53 transformation suppressor gene.
X60019 - Human mRNA for mutated p53 transformation suppressor gene.
X60020 - Human mRNA for mutated p53 transformation suppressor gene.
AB527267 - Synthetic construct DNA, clone: pF1KB8730, Homo sapiens TP53 gene for tumor protein p53, without stop codon, in Flexi system.
JQ026209 - Homo sapiens clone c.672_673ins5 mutated tumor suppressor protein P53 mRNA sequence.
LP866503 - Sequence 57 from Patent WO2017162888.
AY429684 - Homo sapiens tumor suppressor p53 (TP53) mRNA, partial cds.
S66666 - p53=tumor suppressor {alternatively spliced, exon 9-10} [human, Molt-4, T-lymphoblastic leukemia cell line, mRNA PartialMutant, 160 nt].
DL476249 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
DL476265 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941369 - JP 2012152216-A/194: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HV941385 - JP 2012152216-A/210: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798275 - JP 2014236738-A/194: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798291 - JP 2014236738-A/210: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476266 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941386 - JP 2012152216-A/211: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798292 - JP 2014236738-A/211: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
KY907121 - Homo sapiens isolate CC2_TP53 p53 (TP53) mRNA, partial cds.
KY907122 - Homo sapiens isolate CC3_TP53 p53 (TP53) mRNA, partial cds.
KY907123 - Homo sapiens isolate CC5_TP53 p53 (TP53) mRNA, partial cds.
KY907124 - Homo sapiens isolate CC7_TP53 p53 (TP53) mRNA, partial cds.
KY907125 - Homo sapiens isolate CC10_TP53 p53 (TP53) mRNA, partial cds.
KY907126 - Homo sapiens isolate CC11_TP53 p53 (TP53) mRNA, partial cds.
KY907127 - Homo sapiens isolate CC12_TP53 p53 (TP53) mRNA, partial cds.
KY907128 - Homo sapiens isolate CC15_TP53 p53 (TP53) mRNA, partial cds.
KY907129 - Homo sapiens isolate CC17_TP53 p53 (TP53) mRNA, partial cds.
KY907130 - Homo sapiens isolate CC19_TP53 p53 (TP53) mRNA, partial cds.
KY907131 - Homo sapiens isolate CC20_TP53 p53 (TP53) mRNA, partial cds.
KY907132 - Homo sapiens isolate CC21_TP53 p53 (TP53) mRNA, partial cds.
KY907133 - Homo sapiens isolate CC22_TP53 p53 (TP53) mRNA, partial cds.
KY907134 - Homo sapiens isolate CC23_TP53 p53 (TP53) mRNA, partial cds.
KY907135 - Homo sapiens isolate CC24_TP53 p53 (TP53) mRNA, partial cds.
KY907136 - Homo sapiens isolate CC26_TP53 p53 (TP53) mRNA, partial cds.
KY907137 - Homo sapiens isolate CC27_TP53 p53 (TP53) mRNA, partial cds.
KY907138 - Homo sapiens isolate CC28_TP53 p53 (TP53) mRNA, partial cds.
KY907139 - Homo sapiens isolate CC29_TP53 p53 (TP53) mRNA, partial cds.
KY907140 - Homo sapiens isolate CC30_TP53 p53 (TP53) mRNA, partial cds.
KY907141 - Homo sapiens isolate CC33_TP53 p53 (TP53) mRNA, partial cds.
KY907142 - Homo sapiens isolate CC34_TP53 p53 (TP53) mRNA, partial cds.
KY907143 - Homo sapiens isolate CC35_TP53 p53 (TP53) mRNA, partial cds.
KY907144 - Homo sapiens isolate CC36_TP53 p53 (TP53) mRNA, partial cds.
KY907145 - Homo sapiens isolate CC37_TP53 p53 (TP53) mRNA, partial cds.
KY907146 - Homo sapiens isolate CC38_TP53 p53 (TP53) mRNA, partial cds.
DL476283 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941403 - JP 2012152216-A/228: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798309 - JP 2014236738-A/228: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476292 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941412 - JP 2012152216-A/237: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798318 - JP 2014236738-A/237: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476274 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941394 - JP 2012152216-A/219: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798300 - JP 2014236738-A/219: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476250 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941370 - JP 2012152216-A/195: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798276 - JP 2014236738-A/195: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476245 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941365 - JP 2012152216-A/190: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798271 - JP 2014236738-A/190: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
KC820708 - Homo sapiens isolate 1 tumor protein 53 (TP53) mRNA, partial cds.
KC820709 - Homo sapiens isolate 2 tumor protein 53 (TP53) mRNA, partial cds.
KC820710 - Homo sapiens isolate 3 tumor protein 53 (TP53) mRNA, partial cds.
KC820711 - Homo sapiens isolate 4 tumor protein 53 (TP53) mRNA, partial cds.
KC820712 - Homo sapiens isolate 5 tumor protein 53 (TP53) mRNA, partial cds.
KC820713 - Homo sapiens isolate 6 tumor protein 53 (TP53) mRNA, partial cds.
KC820714 - Homo sapiens isolate 7 tumor protein 53 (TP53) mRNA, partial cds.
KC820715 - Homo sapiens isolate 8 tumor protein 53 (TP53) mRNA, partial cds.
KC820716 - Homo sapiens isolate 9 tumor protein 53 (TP53) mRNA, partial cds.
KC820717 - Homo sapiens isolate 10 tumor protein 53 (TP53) mRNA, partial cds.
KC820718 - Homo sapiens isolate 11 tumor protein 53 (TP53) mRNA, partial cds.
KC820719 - Homo sapiens isolate 12 tumor protein 53 (TP53) mRNA, partial cds.
KC820720 - Homo sapiens isolate 13 tumor protein 53 (TP53) mRNA, partial cds.
KC820721 - Homo sapiens isolate 14 tumor protein 53 (TP53) mRNA, partial cds.
KC820722 - Homo sapiens isolate 15 tumor protein 53 (TP53) mRNA, partial cds.
KC820723 - Homo sapiens isolate 16 tumor protein 53 (TP53) mRNA, partial cds.
KC820724 - Homo sapiens isolate 17 tumor protein 53 (TP53) mRNA, partial cds.
KC820725 - Homo sapiens isolate 18 tumor protein 53 (TP53) mRNA, partial cds.
KC820726 - Homo sapiens isolate 19 tumor protein 53 (TP53) mRNA, partial cds.
KC820727 - Homo sapiens isolate 20 tumor protein 53 (TP53) mRNA, partial cds.
KC820728 - Homo sapiens isolate 21 tumor protein 53 (TP53) mRNA, partial cds.
KC820729 - Homo sapiens isolate 22 tumor protein 53 (TP53) mRNA, partial cds.
KC820730 - Homo sapiens isolate 23 tumor protein 53 (TP53) mRNA, partial cds.
KC820731 - Homo sapiens isolate 24 tumor protein 53 (TP53) mRNA, partial cds.
KC820732 - Homo sapiens isolate 25 tumor protein 53 (TP53) mRNA, partial cds.
KC820733 - Homo sapiens isolate 26 tumor protein 53 (TP53) mRNA, partial cds.
KC820734 - Homo sapiens isolate 27 tumor protein 53 (TP53) mRNA, partial cds.
KC820735 - Homo sapiens isolate 28 tumor protein 53 (TP53) mRNA, partial cds.
KC820736 - Homo sapiens isolate 29 tumor protein 53 (TP53) mRNA, partial cds.
KC820737 - Homo sapiens isolate 30 tumor protein 53 (TP53) mRNA, partial cds.
KC820738 - Homo sapiens isolate 31 tumor protein 53 (TP53) mRNA, partial cds.
KC820739 - Homo sapiens isolate 32 tumor protein 53 (TP53) mRNA, partial cds.
KC820740 - Homo sapiens isolate 33 tumor protein 53 (TP53) mRNA, partial cds.
KC820741 - Homo sapiens isolate 34 tumor protein 53 (TP53) mRNA, partial cds.
KC820742 - Homo sapiens isolate 35 tumor protein 53 (TP53) mRNA, partial cds.
KC820743 - Homo sapiens isolate 36 tumor protein 53 (TP53) mRNA, partial cds.
KC820744 - Homo sapiens isolate 37 tumor protein 53 (TP53) mRNA, partial cds.
KC820745 - Homo sapiens isolate 38 tumor protein 53 (TP53) mRNA, partial cds.
KC820746 - Homo sapiens isolate 39 tumor protein 53 (TP53) mRNA, partial cds.
KC820747 - Homo sapiens isolate 40 tumor protein 53 (TP53) mRNA, partial cds.
KC820748 - Homo sapiens isolate 41 tumor protein 53 (TP53) mRNA, partial cds.
KC820749 - Homo sapiens isolate 42 tumor protein 53 (TP53) mRNA, partial cds.
KC820750 - Homo sapiens isolate 43 tumor protein 53 (TP53) mRNA, partial cds.
KC820751 - Homo sapiens isolate 44 tumor protein 53 (TP53) mRNA, partial cds.
KC820752 - Homo sapiens isolate 45 tumor protein 53 (TP53) mRNA, partial cds.
KC820753 - Homo sapiens isolate 46 tumor protein 53 (TP53) mRNA, partial cds.
KC820754 - Homo sapiens isolate 47 tumor protein 53 (TP53) mRNA, partial cds.
KC820755 - Homo sapiens isolate 48 tumor protein 53 (TP53) mRNA, partial cds.
KC820756 - Homo sapiens isolate 49 tumor protein 53 (TP53) mRNA, partial cds.
KC820757 - Homo sapiens isolate 50 tumor protein 53 (TP53) mRNA, partial cds.
KC820758 - Homo sapiens isolate 51 tumor protein 53 (TP53) mRNA, partial cds.
KC820759 - Homo sapiens isolate 52 mutant tumor protein 53 (TP53) mRNA, partial cds.
KC820760 - Homo sapiens isolate 53 tumor protein 53 (TP53) mRNA, partial cds.
KC820761 - Homo sapiens isolate 54 tumor protein 53 (TP53) mRNA, partial cds.
KC820762 - Homo sapiens isolate 55 tumor protein 53 (TP53) mRNA, partial cds.
KC820763 - Homo sapiens isolate 56 tumor protein 53 (TP53) mRNA, partial cds.
KC820764 - Homo sapiens isolate 57 tumor protein 53 (TP53) mRNA, partial cds.
KC820765 - Homo sapiens isolate 58 tumor protein 53 (TP53) mRNA, partial cds.
KC820766 - Homo sapiens isolate 59 tumor protein 53 (TP53) mRNA, partial cds.
KC820767 - Homo sapiens isolate 60 tumor protein 53 (TP53) mRNA, partial cds.
KC820768 - Homo sapiens isolate 61 tumor protein 53 (TP53) mRNA, partial cds.
KC820769 - Homo sapiens isolate 62 tumor protein 53 (TP53) mRNA, partial cds.
KC820770 - Homo sapiens isolate 63 tumor protein 53 (TP53) mRNA, partial cds.
KC820771 - Homo sapiens isolate 64 tumor protein 53 (TP53) mRNA, partial cds.
KC820772 - Homo sapiens isolate 65 tumor protein 53 (TP53) mRNA, partial cds.
KC820773 - Homo sapiens isolate 66 tumor protein 53 (TP53) mRNA, partial cds.
KC820774 - Homo sapiens isolate 67 tumor protein 53 (TP53) mRNA, partial cds.
KC820775 - Homo sapiens isolate 68 tumor protein 53 (TP53) mRNA, partial cds.
KC820776 - Homo sapiens isolate 69 tumor protein 53 (TP53) mRNA, partial cds.
KC820777 - Homo sapiens isolate 70 tumor protein 53 (TP53) mRNA, partial cds.
KC820778 - Homo sapiens isolate 71 tumor protein 53 (TP53) mRNA, partial cds.
KC820779 - Homo sapiens isolate 72 tumor protein 53 (TP53) mRNA, partial cds.
KC820780 - Homo sapiens isolate 73 tumor protein 53 (TP53) mRNA, partial cds.
KC820781 - Homo sapiens isolate 74 tumor protein 53 (TP53) mRNA, partial cds.
KC820782 - Homo sapiens isolate 75 tumor protein 53 (TP53) mRNA, partial cds.
KC820783 - Homo sapiens isolate 76 tumor protein 53 (TP53) mRNA, partial cds.
KC820784 - Homo sapiens isolate 77 tumor protein 53 (TP53) mRNA, partial cds.
KC820785 - Homo sapiens isolate 78 tumor protein 53 (TP53) mRNA, partial cds.
KC820786 - Homo sapiens isolate 79 tumor protein 53 (TP53) mRNA, partial cds.
DL476251 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941371 - JP 2012152216-A/196: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798277 - JP 2014236738-A/196: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476297 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
DL476305 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941417 - JP 2012152216-A/242: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HV941425 - JP 2012152216-A/250: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798323 - JP 2014236738-A/242: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798331 - JP 2014236738-A/250: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476301 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941421 - JP 2012152216-A/246: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798327 - JP 2014236738-A/246: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476299 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941419 - JP 2012152216-A/244: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798325 - JP 2014236738-A/244: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476306 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941426 - JP 2012152216-A/251: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798332 - JP 2014236738-A/251: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476302 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941422 - JP 2012152216-A/247: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798328 - JP 2014236738-A/247: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476300 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941420 - JP 2012152216-A/245: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798326 - JP 2014236738-A/245: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476303 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941423 - JP 2012152216-A/248: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798329 - JP 2014236738-A/248: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DQ648884 - Homo sapiens p53-Ex4 isoform (TP53) mRNA, partial cds, alternatively spliced.
DQ648885 - Homo sapiens p53-Ex(2-4) isoform (TP53) mRNA, partial cds, alternatively spliced.
X60010 - Human mRNA for mutated p53 transformation suppressor gene.
DL476293 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941413 - JP 2012152216-A/238: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798319 - JP 2014236738-A/238: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476284 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941404 - JP 2012152216-A/229: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798310 - JP 2014236738-A/229: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476285 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941405 - JP 2012152216-A/230: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798311 - JP 2014236738-A/230: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476267 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941387 - JP 2012152216-A/212: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798293 - JP 2014236738-A/212: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476291 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941411 - JP 2012152216-A/236: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798317 - JP 2014236738-A/236: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476276 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941396 - JP 2012152216-A/221: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798302 - JP 2014236738-A/221: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476277 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941397 - JP 2012152216-A/222: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798303 - JP 2014236738-A/222: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476268 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941388 - JP 2012152216-A/213: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798294 - JP 2014236738-A/213: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476286 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941406 - JP 2012152216-A/231: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798312 - JP 2014236738-A/231: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476287 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941407 - JP 2012152216-A/232: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798313 - JP 2014236738-A/232: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476278 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941398 - JP 2012152216-A/223: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798304 - JP 2014236738-A/223: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476279 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941399 - JP 2012152216-A/224: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798305 - JP 2014236738-A/224: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476269 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941389 - JP 2012152216-A/214: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798295 - JP 2014236738-A/214: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476280 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941400 - JP 2012152216-A/225: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798306 - JP 2014236738-A/225: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476288 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941408 - JP 2012152216-A/233: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798314 - JP 2014236738-A/233: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476281 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941401 - JP 2012152216-A/226: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798307 - JP 2014236738-A/226: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476263 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941383 - JP 2012152216-A/208: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798289 - JP 2014236738-A/208: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476282 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941402 - JP 2012152216-A/227: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798308 - JP 2014236738-A/227: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476270 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941390 - JP 2012152216-A/215: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798296 - JP 2014236738-A/215: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476264 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941384 - JP 2012152216-A/209: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798290 - JP 2014236738-A/209: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DQ485152 - Homo sapiens cell-line Hec50co truncated p53 splice variant (TP53) mRNA, partial cds, aberrantly spliced.
DL476289 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941409 - JP 2012152216-A/234: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798315 - JP 2014236738-A/234: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476273 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941393 - JP 2012152216-A/218: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798299 - JP 2014236738-A/218: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476246 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941366 - JP 2012152216-A/191: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798272 - JP 2014236738-A/191: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
AK303277 - Homo sapiens cDNA FLJ50936 complete cds, highly similar to Cellular tumor antigen p53.
CU678522 - Synthetic construct Homo sapiens gateway clone IMAGE:100019213 5' read TP53 mRNA.
DL476256 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941376 - JP 2012152216-A/201: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798282 - JP 2014236738-A/201: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476257 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941377 - JP 2012152216-A/202: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798283 - JP 2014236738-A/202: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476275 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941395 - JP 2012152216-A/220: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798301 - JP 2014236738-A/220: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476294 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941414 - JP 2012152216-A/239: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798320 - JP 2014236738-A/239: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476295 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941415 - JP 2012152216-A/240: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798321 - JP 2014236738-A/240: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DQ401704 - Homo sapiens p53deltaEx4 mRNA, partial cds.
DL476259 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941379 - JP 2012152216-A/204: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798285 - JP 2014236738-A/204: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DL476260 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941380 - JP 2012152216-A/205: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798286 - JP 2014236738-A/205: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
DQ648883 - Homo sapiens p53+ins1a isoform (TP53) mRNA, complete sequence, alternatively spliced.
DL476261 - Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Medical Conditions.
HV941381 - JP 2012152216-A/206: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
HW798287 - JP 2014236738-A/206: Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other Diseases.
AY627884 - Homo sapiens p53 tumor suppressor mRNA, 5' UTR and partial cds.
JD116459 - Sequence 97483 from Patent EP1572962.
JD516513 - Sequence 497537 from Patent EP1572962.
JD465582 - Sequence 446606 from Patent EP1572962.
JD396487 - Sequence 377511 from Patent EP1572962.
JD300651 - Sequence 281675 from Patent EP1572962.
JD412359 - Sequence 393383 from Patent EP1572962.
MP140196 - Sequence 5 from Patent EP3444349.
MP140197 - Sequence 6 from Patent EP3444349.
MP140198 - Sequence 7 from Patent EP3444349.
MP140192 - Sequence 1 from Patent EP3444349.
MP140193 - Sequence 2 from Patent EP3444349.
MP140194 - Sequence 3 from Patent EP3444349.
MP140195 - Sequence 4 from Patent EP3444349.

-  Biochemical and Signaling Pathways
  KEGG - Kyoto Encyclopedia of Genes and Genomes
hsa04010 - MAPK signaling pathway
hsa04110 - Cell cycle
hsa04115 - p53 signaling pathway
hsa04210 - Apoptosis
hsa04310 - Wnt signaling pathway
hsa04722 - Neurotrophin signaling pathway
hsa05014 - Amyotrophic lateral sclerosis (ALS)
hsa05016 - Huntington's disease
hsa05200 - Pathways in cancer
hsa05210 - Colorectal cancer
hsa05212 - Pancreatic cancer
hsa05213 - Endometrial cancer
hsa05214 - Glioma
hsa05215 - Prostate cancer
hsa05216 - Thyroid cancer
hsa05217 - Basal cell carcinoma
hsa05218 - Melanoma
hsa05219 - Bladder cancer
hsa05220 - Chronic myeloid leukemia
hsa05222 - Small cell lung cancer
hsa05223 - Non-small cell lung cancer

BioCarta from NCI Cancer Genome Anatomy Project
h_atmPathway - ATM Signaling Pathway
h_telPathway - Telomeres, Telomerase, Cellular Aging, and Immortality
h_p53hypoxiaPathway - Hypoxia and p53 in the Cardiovascular system
h_pmlPathway - Regulation of transcriptional activity by PML
h_btg2Pathway - BTG family proteins and cell cycle regulation
h_rbPathway - RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage
h_rnaPathway - Double Stranded RNA Induced Gene Expression
h_tertpathway - Overview of telomerase protein component gene hTert Transcriptional Regulation
h_tidPathway - Chaperones modulate interferon Signaling Pathway
h_chemicalPathway - Apoptotic Signaling in Response to DNA Damage
h_plk3Pathway - Regulation of cell cycle progression by Plk3
h_ctcfPathway - CTCF: First Multivalent Nuclear Factor
h_EfpPathway - Estrogen-responsive protein Efp controls cell cycle and breast tumors growth
h_atrbrcaPathway - Role of BRCA1, BRCA2 and ATR in Cancer Susceptibility
h_g1Pathway - Cell Cycle: G1/S Check Point
h_arfPathway - Tumor Suppressor Arf Inhibits Ribosomal Biogenesis
h_g2Pathway - Cell Cycle: G2/M Checkpoint
h_p53Pathway - p53 Signaling Pathway

Reactome (by CSHL, EBI, and GO)

Protein P04637 (Reactome details) participates in the following event(s):

R-HSA-2997706 MDM2 SUMOylates TP53 with SUMO2,3
R-HSA-6804762 TP53 forms homotetramers
R-HSA-992696 p53, SIN3A and MYB form a complex
R-NUL-992753 p53 and Sin3a bind c-Myb
R-HSA-3221982 BANP binds TP53
R-HSA-3239014 MAPKAPK5 phosphorylates TP53
R-HSA-4395236 TP53 binds promoters of MIR34 genes
R-HSA-5628899 TP53 binds the TIGAR gene
R-HSA-5629187 TP53 binds regulatory elements of SESN1,2,3 genes
R-HSA-5632759 TP53 binds the SCO2 gene
R-HSA-5632887 TP53 binds the RRM2B gene
R-HSA-5632914 TP53 binds the GLS2 promoter
R-HSA-5632939 TP53 binds the PTEN promoter
R-HSA-5633460 MDM2 binds TP53
R-HSA-5693609 ATM phosphorylates TP53 at S15
R-HSA-6791409 TP53 binds the CCNG1 gene
R-HSA-6799332 ATR phosphorylates TP53
R-HSA-6799431 TP53 binds HIPK1
R-HSA-6805035 TP53 binds STK11 and NUAK1
R-HSA-6805103 AURKA phosphorylates TP53
R-HSA-6805109 CDK2 phosphorylates TP53
R-HSA-6805276 CDK5 phosphorylates TP53
R-HSA-6805399 TAF1 phosphorylates TP53
R-HSA-6805470 AMPK phosphorylates TP53
R-HSA-6805479 TP53RK phosphorylates TP53
R-HSA-6805755 EHMT1:EHMT2 dimethylates TP53
R-HSA-8952128 RUNX3 binds TP53
R-HSA-3215310 USP7 deubiquitinates TP53 and counteracts MDM2
R-HSA-6804996 p14-ARF sequesters MDM2
R-HSA-5689973 USP10,USP24,USP42 deubiquitinate TP53
R-HSA-69685 CHEK2 phosphorylates TP53
R-HSA-3786258 TP53 binds the CDKN1A promoter
R-HSA-6799246 CHEK1 phosphorylates TP53
R-HSA-6805285 PLK3 phosphorylates TP53
R-HSA-264435 Dissociation of the COP1-p53 complex
R-HSA-3215152 TP53 in complex with EP300, PRMT1 and CARM1 binds the GADD45A promoter
R-HSA-3215251 TP53INP1 and HIPK2 bind TP53
R-HSA-3222093 BRD7 binds TP53 and EP300
R-HSA-3222128 NOC2L binds TP53
R-HSA-3222237 SMYD2 methylates TP53
R-HSA-3700997 TP53 binds the MDM2 gene
R-HSA-4331331 TP53 binds the PMAIP1 (NOXA) promoter
R-HSA-5633295 TP53 binds the NDRG1 gene promoter
R-HSA-5633414 TP53 binds TNFRSF10A,TNFRSF10B,TNFRSF10C,TNFRSF10D genes
R-HSA-6791285 TP53 binds the BID gene promoter
R-HSA-6791302 TP53 binds the AIFM2 gene promoter
R-HSA-6791327 TP53 binds the BCL2L14 gene
R-HSA-6791349 TP53 binds the APAF1 gene promoter
R-HSA-6791387 TP53 binds the ARID3A gene
R-HSA-6796649 TP53 binds the CCNK gene
R-HSA-6797766 TP53 binds the BIRC5 gene
R-HSA-6797993 TP53 and CREBBP bind BNIP3L gene
R-HSA-6798020 TP53 binds the BTG2 gene
R-HSA-6798129 TP53 binds the CASP6 gene
R-HSA-6798138 TP53 binds the CASP10 gene
R-HSA-6798282 TP53 and E2F4 bind the CDC25C gene
R-HSA-6798304 TP53 binds the E2F7 gene
R-HSA-6798374 DYRK2 phosphorylates TP53
R-HSA-6799418 TP53 binds the TP53INP1 gene
R-HSA-6800042 TP53 binds the IGFBP3 gene
R-HSA-6800253 TP53 binds the BCL6 gene
R-HSA-6800279 TP53 binds the PIDD1 gene
R-HSA-6801087 TP53 binds the RABGGTA gene
R-HSA-6801166 TP53 binds the STEAP3 gene
R-HSA-6801209 TP53 binds the TRIAP1 gene
R-HSA-6801355 TP53 binds the NLRC4 gene
R-HSA-6801641 TP53 binds the PLK2 gene
R-HSA-6802165 TP53 binds the PLK3 gene
R-HSA-6803391 TP53 binds the PCBP4 gene
R-HSA-6803425 TP53 binds ZNF385A gene
R-HSA-6803719 TP53 binds ZNF385A
R-HSA-6803914 TP53 binds the RGCC gene
R-HSA-6803935 TP53 binds the PLAGL1 gene
R-HSA-6804191 TP53 binds the PRDM1 gene
R-HSA-6804242 TP53 binds the complex of JMY, EP300 and TTC5
R-HSA-6804402 TP53 binds POU4F1
R-HSA-6804425 TP53 binds POU4F2
R-HSA-6804441 RNF34 or RFFL ubiquitinates phosphorylated TP53
R-HSA-6805059 CK2:FACT phosphorylates TP53
R-HSA-6805620 KAT6A and PML bind TP53
R-HSA-6805730 SETD9 methylates TP53
R-HSA-6805740 SETD8 methylates TP53
R-HSA-6806408 TP53 binds the PMS2 gene
R-HSA-6806412 TP53 and AP-1 bind the MSH2 promoter
R-HSA-6806413 TP53 binds the MLH1 gene
R-HSA-6806417 TP53 binds the DDB2 gene
R-HSA-6806419 TP53 binds the FANCC gene
R-HSA-6811479 ING2 recruits EP300 to TP53
R-HSA-3222020 NUAK1 phosphorylates TP53
R-HSA-3222116 L3MBTL1 binds TP53 monomethylated on K382
R-HSA-3222259 PHF20 binds TP53 dimethylated on K370 and K382
R-HSA-6793685 Ubiquitinated TP53 translocates to the cytosol
R-HSA-8852337 GTSE1 binds TP53
R-HSA-6804879 MDM2 ubiquitinates TP53
R-HSA-6798615 TP53 binds the TP53AIP1 gene
R-HSA-6799409 HIPK2 phosphorylates TP53
R-HSA-390470 Association of CCT/TriC with other substrates during biosynthesis (unknown chaperone)
R-HSA-5690843 OTUB1, (OTUB2) binds RNF128, TRAF3, TRAF6, RHOA
R-HSA-6804998 p14-ARF forms a ternary complex with MDM2 and TP53
R-HSA-3222006 STK11 (LKB1) phosphorylates NUAK1
R-HSA-5632393 TP63/TP53 bind the DDIT4 gene promoter
R-HSA-5689950 USP7 deubiquitinates TP53,MDM2,MDM4,FOXO4, PTEN
R-HSA-4647593 EP400 binds CDKN1A promoter
R-HSA-6811508 ING2-bound EP300 acetylates TP53
R-HSA-5628871 BRD7 promotes EP300-mediated acetylation of TP53
R-HSA-6805122 AURKB binds TP53
R-HSA-6803801 TP53 in complex with ZNF385A binds the CDKN1A promoter
R-HSA-6803858 TP53 binds the SFN gene
R-HSA-6804379 PRMT5 binds TTC5
R-HSA-6805638 KAT6A acetylates TP53
R-HSA-6798082 TP53 family members bind the CASP1 gene
R-HSA-6799761 TP53 binds PPP1R13L
R-HSA-6799777 TP53 family members bind PPP1R13B or TP53BP2
R-HSA-6800836 TP53 or TP63 binds the PERP gene
R-HSA-8852351 GTSE1 promotes translocation of TP53 to the cytosol
R-HSA-6804383 PRMT5 methylates TP53
R-HSA-6805126 AURKB phosphorylates TP53
R-HSA-6805650 MTA2-NuRD complex deacetylates TP53
R-HSA-3700981 TP53 family members bind the BAX promoter
R-HSA-4331340 TP53 binds the BBC3 (PUMA) promoter
R-HSA-6799462 TP53 family members bind the TP53I3 (PIG3) gene promoter
R-HSA-6799815 TP53 family members bind the FAS gene
R-HSA-3232118 SUMOylation of transcription factors
R-HSA-6804754 Regulation of TP53 Expression
R-HSA-983231 Factors involved in megakaryocyte development and platelet production
R-HSA-6804759 Regulation of TP53 Activity through Association with Co-factors
R-HSA-2559580 Oxidative Stress Induced Senescence
R-HSA-6804756 Regulation of TP53 Activity through Phosphorylation
R-HSA-1912408 Pre-NOTCH Transcription and Translation
R-HSA-5628897 TP53 Regulates Metabolic Genes
R-HSA-8943724 Regulation of PTEN gene transcription
R-HSA-69541 Stabilization of p53
R-HSA-6804757 Regulation of TP53 Degradation
R-HSA-2559586 DNA Damage/Telomere Stress Induced Senescence
R-HSA-5693565 Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
R-HSA-69473 G2/M DNA damage checkpoint
R-HSA-6804760 Regulation of TP53 Activity through Methylation
R-HSA-8941855 RUNX3 regulates CDKN1A transcription
R-HSA-2559585 Oncogene Induced Senescence
R-HSA-5689880 Ub-specific processing proteases
R-HSA-6785807 Interleukin-4 and 13 signaling
R-HSA-3108232 SUMO E3 ligases SUMOylate target proteins
R-HSA-6806003 Regulation of TP53 Expression and Degradation
R-HSA-349425 Autodegradation of the E3 ubiquitin ligase COP1
R-HSA-6804114 TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
R-HSA-6804758 Regulation of TP53 Activity through Acetylation
R-HSA-111448 Activation of NOXA and translocation to mitochondria
R-HSA-6803204 TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
R-HSA-6803205 TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
R-HSA-6803211 TP53 Regulates Transcription of Death Receptors and Ligands
R-HSA-6803207 TP53 Regulates Transcription of Caspase Activators and Caspases
R-HSA-6804116 TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
R-HSA-6796648 TP53 Regulates Transcription of DNA Repair Genes
R-HSA-6804115 TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
R-HSA-69895 Transcriptional activation of cell cycle inhibitor p21
R-HSA-6811555 PI5P Regulates TP53 Acetylation
R-HSA-69481 G2/M Checkpoints
R-HSA-8852276 The role of GTSE1 in G2/M progression after G2 checkpoint
R-HSA-390471 Association of TriC/CCT with target proteins during biosynthesis
R-HSA-5689896 Ovarian tumor domain proteases
R-HSA-109582 Hemostasis
R-HSA-5633007 Regulation of TP53 Activity
R-HSA-2559583 Cellular Senescence
R-HSA-1912422 Pre-NOTCH Expression and Processing
R-HSA-3700989 Transcriptional Regulation by TP53
R-HSA-6807070 PTEN Regulation
R-HSA-69563 p53-Dependent G1 DNA Damage Response
R-HSA-5693606 DNA Double Strand Break Response
R-HSA-8878159 Transcriptional regulation by RUNX3
R-HSA-5688426 Deubiquitination
R-HSA-449147 Signaling by Interleukins
R-HSA-2990846 SUMOylation
R-HSA-6791312 TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-114452 Activation of BH3-only proteins
R-HSA-5633008 TP53 Regulates Transcription of Cell Death Genes
R-HSA-69560 Transcriptional activation of p53 responsive genes
R-HSA-69620 Cell Cycle Checkpoints
R-HSA-69275 G2/M Transition
R-HSA-390466 Chaperonin-mediated protein folding
R-HSA-2262752 Cellular responses to stress
R-HSA-157118 Signaling by NOTCH
R-HSA-212436 Generic Transcription Pathway
R-HSA-1257604 PIP3 activates AKT signaling
R-HSA-69580 p53-Dependent G1/S DNA damage checkpoint
R-HSA-5693532 DNA Double-Strand Break Repair
R-HSA-597592 Post-translational protein modification
R-HSA-1280215 Cytokine Signaling in Immune system
R-HSA-139915 Activation of PUMA and translocation to mitochondria
R-HSA-109606 Intrinsic Pathway for Apoptosis
R-HSA-1640170 Cell Cycle
R-HSA-453274 Mitotic G2-G2/M phases
R-HSA-391251 Protein folding
R-HSA-8953897 Cellular responses to external stimuli
R-HSA-162582 Signal Transduction
R-HSA-73857 RNA Polymerase II Transcription
R-HSA-9006925 Intracellular signaling by second messengers
R-HSA-69615 G1/S DNA Damage Checkpoints
R-HSA-73894 DNA Repair
R-HSA-392499 Metabolism of proteins
R-HSA-168256 Immune System
R-HSA-109581 Apoptosis
R-HSA-69278 Cell Cycle (Mitotic)
R-HSA-74160 Gene expression (Transcription)
R-HSA-5357801 Programmed Cell Death

-  Other Names for This Gene
  Alternate Gene Symbols: HW061192, P04637, P53, P53_HUMAN, Q15086, Q15087, Q15088, Q16535, Q16807, Q16808, Q16809, Q16810, Q16811, Q16848, Q2XN98, Q3LRW1, Q3LRW2, Q3LRW3, Q3LRW4, Q3LRW5, Q86UG1, Q8J016, Q99659, Q9BTM4, Q9HAQ8, Q9NP68, Q9NPJ2, Q9NZD0, Q9UBI2, Q9UQ61, uc002gij.1, uc002gij.2, uc002gij.3, uc002gij.4
UCSC ID: uc002gij.4
RefSeq Accession: NM_000546
Protein: P04637 (aka P53_HUMAN)
CCDS: CCDS73969.1

-  GeneReviews for This Gene
  GeneReviews article(s) related to gene TP53:
li-fraumeni (Li-Fraumeni Syndrome)
wilms-ov (Wilms Tumor Predisposition)

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.